Cargando…

Antituberculosis Drug-Induced Hepatotoxicity in IranianTuberculosis Patients: Role of Isoniazid Metabolic Polymorphism

The aim of this study was to determine the association of n-acetyltransferase-2 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in Iranian pulmonary tuberculosis patients. Acetylating phenotypes was studied in 50 Iranian pulmonary tuberculosis patients using metabolic ratio of plasma...

Descripción completa

Detalles Bibliográficos
Autores principales: Sistanizad, Mohammad, Azizi, Ebrahim, Khalili, Hosein, Hajiabdolbaghi, Mahboobeh, Gholami, Kheirollah, Mahjub, Reza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Shaheed Beheshti University of Medical Sciences 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3813031/
https://www.ncbi.nlm.nih.gov/pubmed/24250397
_version_ 1782289033163964416
author Sistanizad, Mohammad
Azizi, Ebrahim
Khalili, Hosein
Hajiabdolbaghi, Mahboobeh
Gholami, Kheirollah
Mahjub, Reza
author_facet Sistanizad, Mohammad
Azizi, Ebrahim
Khalili, Hosein
Hajiabdolbaghi, Mahboobeh
Gholami, Kheirollah
Mahjub, Reza
author_sort Sistanizad, Mohammad
collection PubMed
description The aim of this study was to determine the association of n-acetyltransferase-2 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in Iranian pulmonary tuberculosis patients. Acetylating phenotypes was studied in 50 Iranian pulmonary tuberculosis patients using metabolic ratio of plasma acetyl-Isoniazid to Isoniazid. The association between hepatotoxicity and the n-acetyltransferase-2 phenotype was evaluated by using the chi-square (x(2)) test. The metabolic ratio had a bimodal distribution with an antimode value of 1.0. Based on the metabolic ratio of the mentioned patients, 20 (40%) were slow acetylators and 30 (60%) were fast ones. Hepatotoxicity was manifested in 9 of 20 slow acetylators (45%) and only in 5 of 30 rapid acetylators (16.7%). There was a significant difference in the frequency of hepatotoxicity between the slow and fast acetylators (x(2) = 4.778, and p = 0.03). Sex and age were not found to be risk factors for hepatotoxicity. Our findings show that slow acetylation profile is significantly associated with a higher risk of developing hepatotoxicity due to the anti-TB drugs in Iranian pulmonary tuberculosis patients.
format Online
Article
Text
id pubmed-3813031
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Shaheed Beheshti University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-38130312013-11-18 Antituberculosis Drug-Induced Hepatotoxicity in IranianTuberculosis Patients: Role of Isoniazid Metabolic Polymorphism Sistanizad, Mohammad Azizi, Ebrahim Khalili, Hosein Hajiabdolbaghi, Mahboobeh Gholami, Kheirollah Mahjub, Reza Iran J Pharm Res Original Article The aim of this study was to determine the association of n-acetyltransferase-2 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in Iranian pulmonary tuberculosis patients. Acetylating phenotypes was studied in 50 Iranian pulmonary tuberculosis patients using metabolic ratio of plasma acetyl-Isoniazid to Isoniazid. The association between hepatotoxicity and the n-acetyltransferase-2 phenotype was evaluated by using the chi-square (x(2)) test. The metabolic ratio had a bimodal distribution with an antimode value of 1.0. Based on the metabolic ratio of the mentioned patients, 20 (40%) were slow acetylators and 30 (60%) were fast ones. Hepatotoxicity was manifested in 9 of 20 slow acetylators (45%) and only in 5 of 30 rapid acetylators (16.7%). There was a significant difference in the frequency of hepatotoxicity between the slow and fast acetylators (x(2) = 4.778, and p = 0.03). Sex and age were not found to be risk factors for hepatotoxicity. Our findings show that slow acetylation profile is significantly associated with a higher risk of developing hepatotoxicity due to the anti-TB drugs in Iranian pulmonary tuberculosis patients. Shaheed Beheshti University of Medical Sciences 2011 /pmc/articles/PMC3813031/ /pubmed/24250397 Text en © 2011 by School of Pharmacy, Shaheed Beheshti University of Medical Sciences and Health Services
spellingShingle Original Article
Sistanizad, Mohammad
Azizi, Ebrahim
Khalili, Hosein
Hajiabdolbaghi, Mahboobeh
Gholami, Kheirollah
Mahjub, Reza
Antituberculosis Drug-Induced Hepatotoxicity in IranianTuberculosis Patients: Role of Isoniazid Metabolic Polymorphism
title Antituberculosis Drug-Induced Hepatotoxicity in IranianTuberculosis Patients: Role of Isoniazid Metabolic Polymorphism
title_full Antituberculosis Drug-Induced Hepatotoxicity in IranianTuberculosis Patients: Role of Isoniazid Metabolic Polymorphism
title_fullStr Antituberculosis Drug-Induced Hepatotoxicity in IranianTuberculosis Patients: Role of Isoniazid Metabolic Polymorphism
title_full_unstemmed Antituberculosis Drug-Induced Hepatotoxicity in IranianTuberculosis Patients: Role of Isoniazid Metabolic Polymorphism
title_short Antituberculosis Drug-Induced Hepatotoxicity in IranianTuberculosis Patients: Role of Isoniazid Metabolic Polymorphism
title_sort antituberculosis drug-induced hepatotoxicity in iraniantuberculosis patients: role of isoniazid metabolic polymorphism
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3813031/
https://www.ncbi.nlm.nih.gov/pubmed/24250397
work_keys_str_mv AT sistanizadmohammad antituberculosisdruginducedhepatotoxicityiniraniantuberculosispatientsroleofisoniazidmetabolicpolymorphism
AT aziziebrahim antituberculosisdruginducedhepatotoxicityiniraniantuberculosispatientsroleofisoniazidmetabolicpolymorphism
AT khalilihosein antituberculosisdruginducedhepatotoxicityiniraniantuberculosispatientsroleofisoniazidmetabolicpolymorphism
AT hajiabdolbaghimahboobeh antituberculosisdruginducedhepatotoxicityiniraniantuberculosispatientsroleofisoniazidmetabolicpolymorphism
AT gholamikheirollah antituberculosisdruginducedhepatotoxicityiniraniantuberculosispatientsroleofisoniazidmetabolicpolymorphism
AT mahjubreza antituberculosisdruginducedhepatotoxicityiniraniantuberculosispatientsroleofisoniazidmetabolicpolymorphism